Contact | Print version | PDF version | Send article | RSS feed

RP-606 rights revert to Medivir

13 Dec 2005 - Medivir announced that all rights relating to the development of RP-606 (MIV-606), an oral antiviral being developed for the treatment of herpes zoster (shingles) and post-herpetic neuralgia (PHN), the chronic pain which is associated with shingles, have been reverted to Medivir. The reversion is effected by way of a mutual termination of the license agreement with Reliant Pharmaceuticals, Inc., which is now focusing on the marketing and development of its portfolio of cardiovascular products.
 
"During the autumn Medivir has intensified its efforts to find an appropriate way forward for its shingles project MIV-606. With the termination of the Medivir-Reliant licensing agreement for MIV-606, all rights as well as all clinical and other data developed during the term of the agreement will be reverted to Medivir", says Medivir's CEO Lars Adlersson.